Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 7/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026484 | 0.89 | MTOR (0.49) | MTORHTR1AHTR2AHTR7HTR6 | |
| SCHEMBL994392 | 0.88 | MTOR (0.48) | MTORCSNK1DCSNK1G2 | |
| SCHEMBL12928937 | 0.88 | MTOR (0.48) | MTORCSNK1DCSNK1G2 | |
| SCHEMBL1557700 | 0.82 | MTOR (0.53) | MTOR | |
| SCHEMBL1025189 | 0.82 | MTOR (0.54) | MTORHTR1AHTR2AHTR7HTR6 | |
| SCHEMBL15747832 | 0.82 | MTOR (0.42) | MTORMAPTSTK17ACSNK1DCSNK1G2 | |
| SCHEMBL31439343 | 0.82 | MTOR (0.42) | MTORMAPTSTK17ACSNK1DCSNK1G2 | |
| SCHEMBL12266652 | 0.82 | MTOR (0.71) | MTOR | |
| SCHEMBL2253904 | 0.81 | L3MBTL1 (0.54) | HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL9901397 | 0.77 | MTOR (0.38) | MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637670-B2 | Imidazo [4,5-C]quinoline derivatives and their use in the treatment of tumors and/or inflammation | Piramal Enterprises Limited (IN) | 2014-01-28 | — | — | US | disclosed |
| EP-2448937-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | Piramal Life Sciences Limited (IN) | 2012-05-09 | — | — | EP | disclosed |
| US-20120108627-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | Piramal Enterprises Limited (IN) | 2012-05-03 | — | — | US | disclosed |
| WO-2011001212-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108627-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | IL6, RPS6KA6, MTOR | MTOR 3/4885HTR1A 4222/4885HTR2A 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.